The case for & against
Bull & Bear analysis
Bearish
IM Cannabis Corp. (NASDAQ:IMCC) is a Canadian-based cannabis company focused on the cultivation, distribution, and provision of high-quality cannabis products. Positioned in the rapidly evolving cannabis market, IMCC aims to leverage its strong operational capabilities to expand its presence in both domestic and international markets. The company is a key player in the expanding cannabis sector, which is supported by ongoing legalization trends and shifts in consumer preferences towards cannabis products in various forms.
Bull says
- ↑30-for-1 consolidation trims shares to 618,899 for Nasdaq compliance
- ↑Established in high-growth legal markets positions IMCC for demand gains
- ↑High ROE and positive cash flow underline profitability strength
- ↑Low leverage and solid balance sheet mitigate financial risk
- ↑Upward earnings revisions and strong momentum factors attract investors
- ↑Nasdaq compliance may boost stability and institutional appeal
Bear says
- ↓Per-share valuation elevated after 30-for-1 consolidation
- ↓Negative earnings yield raises profitability concerns relative to price
- ↓Elevated short interest may intensify downward pressure
- ↓Regulatory volatility and sector competition threaten revenue stability
- ↓High market competition limits IMCC’s growth moat
- ↓Liquidity and volatility risks persist amid market fluctuations
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 07-30-2026neutral
Transcript signals
Bull points
- On April 1st, the German government legalized cannabis. On April 30th, the Associated Press reported that there is an indication that the US Drug Enforcement Administration will reclassify cannabis as less dangerous drug, placing it at the same level as other medications.
- In April, our monthly sales were just about double the monthly average of the last six months.
- We believe that by facilitating the access to medical cannabis for many new patients, the new regulations will transform the medical cannabis market in Israel.
Bear points
- Revenues for Q1 2024 were $12.1 million compared to $12.5 million in Q1 2023, a decrease of 3%. The decrease is mainly due to an exchange rate effect of about $0.2 million and decrease in average price per sale due to increased competition.
- Gross profit for Q1 2024 was $1.8 million, compared to $2.9 million in Q1 2023, a decrease of 39%. The downside is attributed mainly to the slow moving stock that was moved out at the lower prices and an exchange of differences totaling $0.4 million and $0.64 million cost of sales due to the inventory erase of the slow moving stock.
- Net loss from continuing operations in Q1 2024 was $6 million compared to $0.9 million in Q1 2023. Diluted loss per share in Q1 2024 was $0.42 compared to a loss of $0.05 per share in Q1 2023.
Read full transcript analysis ›